Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models

H Hedlund1, P Hedlund

  • 1Institute of Surgery, Bergen University, Norway.

Scandinavian Journal of Urology and Nephrology. Supplementum
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression and distribution of key proteins of the endocannabinoid system in the human seminal vesicles.

Andrologia·2017
Same author

Expression and distribution of the transient receptor potential cationic channel A1 (TRPA1) in the human clitoris-comparison to male penile erectile tissue.

International journal of impotence research·2017
Same author

Protein kinase enzymes in the human vagina-relation to key mediators of the cyclic AMP and cyclic GMP pathways.

International journal of impotence research·2017
Same author

Treatment of full thickness focal cartilage lesions with a metallic resurfacing implant in a sheep animal model, 1 year evaluation.

Osteoarthritis and cartilage·2015
Same author

Pelvic nerve injury negatively impacts female genital blood flow and induces vaginal fibrosis-implications for human nerve-sparing radical hysterectomy.

BJOG : an international journal of obstetrics and gynaecology·2015
Same author

Expression and distribution of the transient receptor potential cationic channel ankyrin 1 (TRPA1) in the human vagina.

International journal of impotence research·2014
Same journal

Bladder cancer-from pathogenesis to prevention, 2008. Proceedings of an international consultation organized by the WHO Collaborating Center for Urologic Tumors. April 24-25, 2008. Stockholm, Sweden.

Scandinavian journal of urology and nephrology. Supplementum·2009
Same journal

The global burden of urinary bladder cancer.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

Bladder cancer: chemoprevention, complementary approaches and budgetary considerations.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

Combining a molecular profile with a clinical and pathological profile: biostatistical considerations.

Scandinavian journal of urology and nephrology. Supplementum·2008
Same journal

How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.

Scandinavian journal of urology and nephrology. Supplementum·2008
See all related articles

Pharmacotherapy for erectile dysfunction (ED) has evolved, with intracavernosal injections becoming a standard. Combination therapies, including prostaglandin E1 (PGE1), offer improved efficacy and reduced side effects for ED treatment.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Erectile dysfunction (ED) treatment historically relied on penile implants or psychogenic impotence diagnoses.
  • Pharmacotherapy via self-injection programs emerged as a significant advancement for ED management.
  • Intracavernosal injections are now considered a gold standard in treating ED.

Purpose of the Study:

  • To review the evolution and current status of pharmacotherapy for erectile dysfunction.
  • To discuss the development of combination therapies for intracavernosal injections.
  • To explore emerging oral treatments for ED.

Main Methods:

  • Review of historical and current treatment modalities for ED.
  • Analysis of pharmacotherapy, including monotherapy and combination injections.
  • Consideration of alternative delivery methods and novel oral agents.

Related Experiment Videos

Main Results:

  • Papaverine monotherapy for ED was associated with significant side effects, leading to its abandonment.
  • Combination intracavernosal injections, particularly those including prostaglandin E1 (PGE1), offer improved efficacy and reduced adverse events.
  • PGE1 is FDA-approved and widely registered globally for ED treatment.
  • Alternative combinations and delivery routes (transdermal, intraurethral) are being investigated.
  • Oral phosphodiesterase inhibitors show promise for psychogenic impotence.

Conclusions:

  • Intracavernosal pharmacotherapy, especially with combination agents like PGE1, represents a highly effective treatment for ED.
  • Ongoing research into novel oral agents may offer new non-invasive options for ED management.
  • The field continues to advance, seeking safer and more effective ED treatments.